Michelle Geerts
Physician Assistant · Rocklin, CANPI 1396415188
Payments from drug & device makers
Across 438 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Novo Nordisk$959
- Boehringer Ingelheim$655
- AstraZeneca$633
- Lilly USA, LLC$583
- plus $3K from 33 others
What the payments were for
- Food & beverage$8,299100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $1,414 |
| GSK | 52 | $1,012 |
| Novo Nordisk | 67 | $959 |
| Boehringer Ingelheim | 35 | $655 |
| AstraZeneca(2 entities) | 26 | $633 |
| Lilly USA, LLC | 34 | $583 |
| Pfizer | 34 | $563 |
| Astellas Pharma US Inc | 14 | $283 |
| Amgen | 12 | $242 |
| Bayer | 9 | $223 |
| Exact Sciences | 8 | $175 |
| Boston Scientific | 7 | $156 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $144 |
| Collegium Pharmaceutical, Inc. | 7 | $138 |
| Merck | 8 | $125 |
| Phathom Pharmaceuticals, Inc. | 4 | $97 |
| Johnson & Johnson | 4 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $82 |
| Sanofi Pasteur Inc. | 3 | $74 |
| Alnylam Pharmaceuticals Inc. | 4 | $65 |
| Cranial Technologies, Inc | 3 | $55 |
| Dexcom, Inc. | 2 | $52 |
| Hologic Sales And Service, LLC | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Novartis | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Eisai Inc. | 2 | $37 |
| Corium, LLC | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Medtronic | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Abbott | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,299 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $32,672 |
| OzempicSemaglutide | 27 | $28,200 |
| JardianceEmpagliflozin | 11 | $16,262 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,551 |
| LinzessLinaclotide | 17 | $9,484 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,715 |
| DuleraMometasone/Formoterol | 14 | $4,598 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $2,206 |
| PaxlovidNirmatrelvir/Ritonavir | 20 | $1,429 |
| Atorvastatin Calcium | 129 | $1,362 |
| Olmesartan Medoxomil | 22 | $1,361 |
| Levothyroxine Sodium | 103 | $1,327 |
| Losartan Potassium | 96 | $1,236 |
| Gabapentin | 41 | $984 |
| Estradiol | 13 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $563 | $34,10162 claims |
| Novo NordiskOzempic | $959 | $28,20027 claims |
| Boehringer IngelheimJardiance | $655 | $16,26211 claims |
| GSKTrelegy Ellipta | $1,012 | $11,55118 claims |
| AbbVieLinzess | $1,414 | $9,48417 claims |
| AstraZenecaBreztri Aerosphere | $633 | $7,71512 claims |
| MerckDulera | $125 | $4,59814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Rocklin
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Eric CheungLos Angeles$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.